Oxford Gene Technology Ltd. Presents The Latest In Tumour Screening At BSGM
Leading cancer researchers speak on NGS and FISH methods in OGT seminar
Oxford, UK – 16 September 2014. Oxford Gene Technology (OGT), The Molecular Genetics Company, is inviting attendees of the British Society for Genetic Medicine (BSGM) annual conference to its seminar entitled ‘Approaches to tumour screening and therapy stratification: case studies in Non-Small Cell Lung Cancer’ on Monday 22nd September, 13.10-13.50, room 2N.
The conference will take place in Liverpool, UK on 22-24th September and the OGT seminar will include workshops from guest speakers Dr Michael Davies, University of Liverpool Cancer Research Centre and Dr Manisha Maurya, Centre for Molecular Pathology, Royal Marsden Hospital NHS Trust/Institute of Cancer Research.
As the future of cancer treatment is likely to rely on personalised therapy, screening multiple biomarkers to identify targeted therapies will become increasingly important. In the workshop titled ‘Application of the SureSeq™ Solid Tumour Panel to a panel of FFPE (formalin fixed, paraffin embedded) samples of Non-Small Cell Lung Cancer from the Liverpool Lung Project’, Dr Davies will discuss the use of OGT’s targeted sequencing panel for screening multiple cancer biomarkers in clinical research laboratories. The SureSeq Solid Tumour panel encompasses all coding exons of 60 cancer associated genes and has been successfully used to accurately identify mutations across a panel of adenocarcinoma and squamous cell carcinoma samples. In addition, Dr Davies will present a poster at the event which details a validation of the panel in more than 300 clinical research samples, including lung, ovarian, head and neck, oesophageal, pancreatic and sarcoma cancers.
Dr Maurya will also discuss the use of the company’s products in lung cancer, focusing on newly acquired Cytocell fluorescence in situ hybridisation (FISH) probes. Her workshop titled ‘ALK FISH testing in Non-Small Cell Lung Cancer’ describes FISH as the gold standard for testing the Anaplastic Lymphoma Receptor Tyrosine Kinase (ALK) gene, rearrangements of which are present in 4% of non-small cell lung cancers (NSCLC). As NSCLC can be classified into different molecular subtypes, accurate genomic identification of the correct subtype is of paramount importance for targeted treatment; such accuracy is achievable with the Cytocell Aquarius® ALK Breakapart FISH probe.
In addition to the workshops and poster presentation, delegates can find out more about OGT’s products and services at booth 20 (OGT) and 26 (Cytocell) where they can enter a prize draw to win an Amazon Kindle Fire Tablet and book a personal demo of the company’s intuitive cytogenetics and NGS software.
Reserve your place at the seminar or for more information on OGT’s products and services, please visit www.ogt.com.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684
E: contact@ogt.com ; W: www.ogt.com ; Twitter: @OxfordGeneTech
Notes for editors:
About Oxford Gene Technology
Oxford Gene Technology (OGT) provides world-class genetics research solutions to leading clinical and academic research institutions. Founded by Professor Sir Edwin Southern, and with customers in over 60 countries worldwide, OGT has a strong reputation and increasing share in the large and growing genomic medicine market. The Company’s Cytocell®, CytoSure™, SureSeq™ and Genefficiency™ range of fluorescence in situ hybridisation (FISH), microarray and next generation sequencing (NGS) products and services deliver high-quality genetic analysis, enabling accurate identification and confirmation of the causative variation underlying genetic disease.
For more information on the Company, please visit our website at www.ogt.com
CytoSure™, SureSeq™ and Genefficiency™ NGS browser/report: For Research Use Only; Not for Use in Diagnostic Procedures. The Aquarius® IGH Plus Breakapart and Translocation probes have received the CE-IVD label. The products are available for sale from 17th June 2014 in Europe
CytoSure: This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.
Help employers find you! Check out all the jobs and post your resume.